Isomorphic Labs, an Alphabet-backed AI biotech firm, raised $600M to boost its AI drug design engine, expand clinical ...
The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital ...
Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...
The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its ...
The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue ...
4d
GlobalData on MSNGoogle-backed Isomorphic Labs raises $600m to advance AI drug discoveryThe funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.
AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...
Isomorphic Labs says it is advancing drug design programs across multiple therapeutic areas and drug modalities. These ...
Since its launch, Isomorphic Labs has focused on using AI to model biological processes and accelerate drug discovery. The company co-developed AlphaFold 3 with Google DeepMind, an AI model ...
Isomorphic Labs is raising money in its first-ever external funding round from Thrive Capital, a big backer of ChatGPT developer OpenAI ...
Isomorphic Labs, Google’s artificial intelligence drug business, raised $600 million in its first external funding round, the company said on Monday. Thrive Capital, a venture capital firm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results